Chemomab Therapeutics Ltd. (CMMB) Income Statement
CMMB 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCMMB revenue and net income
CMMB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CMMB quarterly EPS vs estimates
Chemomab Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters.
CMMB income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $70,555 | $53,251 | $66,827 | $57,773 | $34,023 | $80,561 | $281,000 | $66,000 | $51,000 | $40,638 |
| Gross profit | −$70,555 | −$53,251 | −$66,827 | −$57,773 | −$34,023 | −$80,561 | −$281,000 | −$66,000 | −$51,000 | −$40,638 |
| Research & development | $5.8M | $11.3M | $18.4M | $17.0M | $6.3M | $3.8M | $13.3M | $7.6M | $6.2M | $2.3M |
| Sales, general & admin | $3.7M | $3.4M | $7.1M | $11.6M | $6.0M | $1.3M | $6.2M | $5.5M | $3.3M | — |
| Total operating expenses | $9.6M | $14.7M | $25.5M | $28.5M | $12.3M | $11.0M | $22.9M | $13.0M | $9.3M | $4.6M |
| Operating income | −$9.6M | −$14.7M | −$25.5M | −$28.5M | −$12.4M | −$11.0M | $27.1M | $12.7M | −$9.4M | −$4.6M |
| Interest income | $572,000 | $794,000 | $1.2M | — | — | $20,000 | $393,000 | $42,000 | $1,439 | — |
| Interest expense | — | — | — | $353,000 | $111,076 | $6,042 | $4.2M | $0 | $5,000 | — |
| Income before taxes | −$9.0M | −$13.9M | −$24.2M | −$28.2M | −$12.5M | −$11.7M | $27.1M | $12.7M | −$9.6M | −$4.6M |
| Income taxes | — | — | −$1 | −$534,000 | $77,000 | −$21,000 | $1 | −$621,000 | $323,000 | $136,241 |
| Net income | −$9.0M | −$13.9M | −$24.2M | −$27.6M | −$12.5M | −$11.7M | $27.1M | $13.3M | −$9.8M | −$4.7M |
| EBITDA | −$9.5M | −$14.7M | −$25.4M | −$28.5M | −$12.3M | −$11.0M | $27.1M | $12.7M | −$9.5M | −$4.6M |
| EPS (diluted) | −$0.17 | −$0.06 | −$0.64 | −$0.48 | −$0.58 | −$8.24 | −$63.20 | −$0.12 | −$817.17 | −$12.79 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | $33,687 | — | — | — | $26,901 | — | $16,173 | $18,932 |
| Gross profit | — | — | — | — | −$33,687 | — | — | — | −$26,901 | — | −$16,173 | −$18,932 |
| Research & development | $1.2M | $925,000 | $1.1M | $960,000 | $1.3M | $2.5M | $2.4M | $2.8M | $2.9M | $3.1M | $3.1M | $3.3M |
| Sales, general & admin | $1.1M | $925,000 | $881,000 | $884,000 | $975,000 | $994,000 | $802,000 | $874,000 | $843,063 | $906,383 | $751,000 | $990,000 |
| Total operating expenses | $2.3M | $1.9M | $2.0M | $1.8M | $2.3M | $3.5M | $3.2M | $3.7M | $3.7M | $4.1M | $3.9M | $4.3M |
| Operating income | −$2.3M | −$1.9M | −$2.0M | −$1.8M | −$2.3M | −$3.5M | −$3.2M | −$3.7M | −$3.8M | −$4.1M | −$3.9M | −$4.4M |
| Interest expense | — | — | — | — | — | — | — | — | $500 | $1,996 | — | — |
| Income before taxes | −$2.2M | −$1.8M | −$1.9M | −$1.7M | −$2.1M | −$3.3M | −$3.0M | −$3.5M | −$3.6M | −$3.9M | −$3.5M | −$4.1M |
| Income taxes | — | — | — | — | — | — | — | — | −$2 | −$16,751 | −$1 | −$54,804 |
| Net income | −$2.2M | −$1.8M | −$1.9M | −$1.7M | −$2.1M | −$3.3M | −$3.0M | −$3.5M | −$3.6M | −$3.9M | −$3.5M | −$4.1M |
| EBITDA | −$2.3M | −$1.8M | −$2.0M | −$1.8M | −$2.2M | −$3.5M | −$3.2M | −$3.7M | −$3.7M | −$4.1M | −$3.9M | −$4.3M |
| EPS (diluted) | −$1.40 | −$0.00 | −$0.00 | −$0.00 | −$0.02 | −$0.14 | −$0.01 | −$0.04 | $0.05 | −$0.06 | −$0.27 | −$0.07 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CMMB's financial statements (latest annual report filed March 23, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CMMB financial results
Chemomab Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $9.0 million. Diluted earnings per share came to −$0.17.
See the CMMB stock overview for the latest quote and news, or the CMMB chart for price history and technical indicators.
CMMB income statement FAQ
Does Chemomab Therapeutics have revenue?
Chemomab Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Chemomab Therapeutics profitable?
No. Chemomab Therapeutics reported a net loss of $9.0 million in fiscal 2025.
How much does Chemomab Therapeutics spend on research and development?
Chemomab Therapeutics spent $5.8 million on research and development in fiscal 2025.
What are Chemomab Therapeutics's earnings per share?
Chemomab Therapeutics earned $-0.17 per diluted share in fiscal 2025, compared with $-0.06 a year earlier.
When does Chemomab Therapeutics's fiscal year end?
Chemomab Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 23, 2026.